MRCT now LifeArc
LifeArc is the new name for MRC Technology, a medical research charity with a 25 year legacy of helping scientists and organisations turn their research into treatments and diagnostics for patients.
LifeArc is pioneering new ways to turn great science into greater patient impact. So far, LifeArc’s work has helped to develop four drugs (Keytruda®, Actemra®, Tysabri® and Entyvio®) and a test for antimicrobial resistance.
The company is investing up to £500 million over the next five years to generate, fund and champion innovations in antimicrobials, neuroscience, personalised oncology and respiratory medicine. Moreover, they are establishing two new funds worth £30 million over four years to progress medical science. A philanthropic fund will provide grants to support academic research funded by other medical research charities and organisations, while a seed fund will invest in early stage therapeutics and biological research.
Finally, LifeArc is creating Communities for Impact: networks bringing together the best partners to drive medical innovation in specific therapeutic and diagnostic areas and will be looking at establishing additional collaborations to help them achieve this.
Watch thier video: https://www.lifearc.org/about/our-vision/
Some further news articles on LifeArc:
https://www.firstwordpharma.com/node/1480287
